Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr
Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.
Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.
Biopharma and CROs to benefit from simplified access to global research sites
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
Tealium for Pharma utilizes deep integration technology and partnerships to deliver an enhanced customer journey in one of healthcare's most vital sectors
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
Subscribe To Our Newsletter & Stay Updated